Header Logo

Connection

Shabir Madhi to Viral Vaccines

This is a "connection" page, showing publications Shabir Madhi has written about Viral Vaccines.
Connection Strength

1,741
  1. Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial. Lancet HIV. 2022 05; 9(5):e309-e322.
    View in: PubMed
    Score: 0,793
  2. WHO guidelines for treatment of severe pneumonia. Lancet. 2007 Aug 04; 370(9585):386-7.
    View in: PubMed
    Score: 0,286
  3. Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers. Vaccine. 2006 Mar 20; 24(13):2432-9.
    View in: PubMed
    Score: 0,255
  4. AstraZeneca COVID-19 vaccine induces robust broadly cross-reactive antibody responses in Malawian adults previously infected with SARS-CoV-2. BMC Med. 2022 03 28; 20(1):128.
    View in: PubMed
    Score: 0,197
  5. COVID-19 vaccines and neglected pregnancy. Lancet. 2020 09 05; 396(10252):e22.
    View in: PubMed
    Score: 0,177
  6. Acute viral bronchiolitis in South Africa: Strategies for management and prevention. S Afr Med J. 2016 Apr; 106(4):27-9.
    View in: PubMed
    Score: 0,033
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.